The company, which is developing antibody-drug conjugates, will use the funding to push its lead drug candidate into trials in additional types of cancer.
"We're so close." Dr. Miriam Merad says NIH cuts could derail life-saving cancer research just as scientists close in on new immune cell–based therapies.
After losing key staff and leadership, FDA rejections of Replimune and Capricor therapies show how instability threatens biotech innovation – and patients.
Former NIH leaders say the worst may be yet to come at NIH, where this year has been "like living in a washing machine."
By O. Rose Broderick
More around STAT
In case you missed it
How ultrasound is ushering a new era of surgery-free cancer treatment, BBC
Engineered “natural killer” cells could help fight cancer. Similar to CAR-T cells, these cells can be programmed to attack cancer cells, MIT News.
Johnson & Johnson ordered to pay $966 million in latest talc lawsuit. The case involves a California woman who died from mesothelioma, a rare cancer, New York Times.
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.
